###begin article-title 0
###xml 79 82 79 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 82 84 82 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 112 116 <span type="species:ncbi:10090">mice</span>
Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 169 172 169 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 232 236 232 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 344 347 344 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 347 349 347 349 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 453 457 453 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
Once metastasis has occurred, the possibility of completely curing breast cancer is unlikely, particularly for the 30 to 40% of cancers overexpressing the gene for HER2/neu. A vaccine targeting p185, the protein product of the HER2/neu gene, could have therapeutic application by controlling the growth and metastasis of highly aggressive HER2/neu+ cells. The purpose of this study was to determine the effectiveness of two gene vaccines targeting HER2/neu in preventive and therapeutic tumor models.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 78 82 78 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 244 247 244 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 316 319 316 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 331 334 331 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 403 406 403 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 4 9 <span type="species:ncbi:10090">mouse</span>
###xml 69 72 <span type="species:ncbi:10116">rat</span>
###xml 139 143 <span type="species:ncbi:10090">mice</span>
###xml 270 283 <span type="species:ncbi:11034">Sindbis virus</span>
###xml 307 310 <span type="species:ncbi:10116">rat</span>
###xml 394 397 <span type="species:ncbi:10116">rat</span>
The mouse breast cancer cell line A2L2, which expresses the gene for rat HER2/neu and hence p185, was injected into the mammary fat pad of mice as a model of solid tumor growth or was injected intravenously as a model of lung metastasis. SINCP-neu, a plasmid containing Sindbis virus genes and the gene for rat HER2/neu, and Adeno-neu, an E1,E2a-deleted adenovirus also containing the gene for rat HER2/neu, were tested as preventive and therapeutic vaccines.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 344 348 344 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 366 370 366 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 423 427 <span type="species:ncbi:10090">mice</span>
###xml 479 483 <span type="species:ncbi:10090">mice</span>
Vaccination with SINCP-neu or Adeno-neu before tumor challenge with A2L2 cells significantly inhibited the growth of the cells injected into the mammary fat or intravenously. Vaccination 2 days after tumor challenge with either vaccine was ineffective in both tumor models. However, therapeutic vaccination in a prime-boost protocol with SINCP-neu followed by Adeno-neu significantly prolonged the overall survival rate of mice injected intravenously with the tumor cells. Naive mice vaccinated using the same prime-boost protocol demonstrated a strong serum immunoglobulin G response and p185-specific cellular immunity, as shown by the results of ELISPOT (enzyme-linked immunospot) analysis for IFNgamma.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 136 139 136 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 168 171 168 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 514 523 514 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 37 41 <span type="species:ncbi:10090">mice</span>
We report herein that vaccination of mice with a plasmid gene vaccine and an adenovirus gene vaccine, each containing the gene for HER2/neu, prevented growth of a HER2/neu-expressing breast cancer cell line injected into the mammary fat pad or intravenously. Sequential administration of the vaccines in a prime-boost protocol was therapeutically effective when tumor cells were injected intravenously before the vaccination. The vaccines induced high levels of both cellular and humoral immunity as determined by in vitro assessment. These findings indicate that clinical evaluation of these vaccines, particularly when used sequentially in a prime-boost protocol, is justified.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 94 95 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 173 177 173 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 178 179 178 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 207 211 207 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 341 344 341 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 344 346 344 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 359 360 359 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 361 362 361 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 517 518 517 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 589 590 589 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 689 691 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 692 694 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 844 846 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 982 984 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 985 987 985 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 646 654 <span type="species:ncbi:9606">patients</span>
Once metastasis has occurred, the possibility of completely curing breast cancer is unlikely [1], particularly for the 30 to 40% of cancers overexpressing the gene for HER2/neu [2]. A vaccine targeting HER2/neu could have considerable preventive and therapeutic application by controlling the growth and metastasis of highly aggressive HER2/neu+ tumor cells [3,4]. Gene vaccines, which are bacterial expression plasmids encoding the DNA sequence for tumor antigens, have induced strong antitumor immunity in animals [5]. Although gene vaccines have shown effectiveness in clinical trials [6-13], only a few trials have been completed in oncology patients, and the results have been mixed [14-19]. However, it was recently demonstrated that a gene vaccine for prostate-specific antigen broke immunologic tolerance and induced cellular immunity [20]. Immunotherapy for cancer using gene vaccines is in its infancy, and the development of new approaches and techniques is anticipated [21-24].
###end p 11
###begin p 12
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 209 215 <span type="species:ncbi:9796">equine</span>
###xml 358 371 <span type="species:ncbi:11034">Sindbis virus</span>
###xml 417 423 <span type="species:ncbi:10090">murine</span>
The fields of gene therapy and gene vaccines have recently converged, as shown by the use of identical delivery systems for both purposes [25]. Alphaviruses such as the Sindbis, Semliki Forest, and Venezuelan equine encephalitis viruses may be used for both gene therapy and gene vaccines [26-28]. We [29] and others [30] have shown that plasmids containing Sindbis virus genes induce excellent antitumor immunity in murine tumor models. Adenoviruses, the workhorse of gene replacement therapy, are quickly moving to the forefront as gene vaccine vectors [31-35]. Unlike alphaviruses, which contain self-replicating RNA [36], adenoviruses contain DNA as their genetic material. For both families of viruses, essential genes for replication or packaging are deleted or mutated to ensure the safety of the gene therapy or gene vaccine vector.
###end p 12
###begin p 13
###xml 466 470 466 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 488 492 488 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 206 212 <span type="species:ncbi:10090">murine</span>
###xml 573 579 <span type="species:ncbi:10090">murine</span>
Although animal models of tumor growth are limited in their ability to represent clinical cancer, models can provide valuable information about drug candidates. We have used both preventive and therapeutic murine tumor models to evaluate the effectiveness of two gene vaccines. Our results demonstrated that each gene vaccine was effective in prevention models, but neither was effective when used in a therapeutic model. However, prime-boost vaccination with SINCP-neu followed by Adeno-neu significantly prolonged the overall survival rate when used therapeutically in a murine model of breast cancer metastasis. This finding indicates that effective vaccine immunotherapy may require treatment with at least two gene vaccines delivered in a precise order.
###end p 13
###begin title 14
Materials and methods
###end title 14
###begin title 15
Tumor cell line and reagents
###end title 15
###begin p 16
###xml 60 63 60 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 190 194 190 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 51 54 <span type="species:ncbi:10116">rat</span>
###xml 86 91 <span type="species:ncbi:10090">mouse</span>
###xml 258 262 <span type="species:ncbi:10090">mice</span>
###xml 405 411 <span type="species:ncbi:9913">bovine</span>
The A2L2 cell line, which expresses high levels of rat HER2/neu, was derived from the mouse tumor cell line 66.3 in our laboratory [29]. The A2L2 cell line has expressed high levels of HER2/neu for more than 5 years and consistently induces tumors in BALB/c mice when injected into a mammary fat pad or intravenously (i.v.). The line was maintained in Eagle's minimal essential medium containing 5% fetal bovine serum, sodium pyruvate, nonessential amino acids, L-glutamine, and vitamins (Gibco, Carlsbad, CA, USA). The monolayer cultures were subdivided at approximately 75% confluence by treatment for 1 to 3 min with 0.25% trypsin and 0.02% ethylenediaminetetraacetic acid (EDTA) at 37degreesC.
###end p 16
###begin title 17
###xml 6 10 6 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
SINCP-neu and Adeno-neu gene vaccines
###end title 17
###begin p 18
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 307 311 307 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 333 337 333 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 444 448 444 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 582 586 582 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 608 612 608 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 665 667 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 34 47 <span type="species:ncbi:11034">Sindbis virus</span>
###xml 303 306 <span type="species:ncbi:10116">rat</span>
###xml 578 581 <span type="species:ncbi:10116">rat</span>
The SINCP plasmid, which contains Sindbis virus genes, was provided by Dr John Polo (Chiron, Emeryville, CA, USA). SINCP is nearly identical to the ELVIS plasmid we previously tested [29] except for an internal ribosome entry site on the 5' side of the insertion point for an antigen gene. The gene for rat neu was excised from pSV2-neu and inserted into SINCP by standard recombinant DNA techniques [29]. The correct insertion of the complete neu gene was confirmed by sequence analysis. The E1,E2a-deleted adenovirus (Adeno) has been described in detail [37,38]. The gene for rat neu was excised from pSV2-neu and incorporated into Adeno as previously described [38].
###end p 18
###begin title 19
Flow cytometric analysis
###end title 19
###begin p 20
###xml 75 79 <span type="species:ncbi:10090">mice</span>
###xml 252 256 <span type="species:ncbi:9925">goat</span>
###xml 620 626 <span type="species:ncbi:9986">rabbit</span>
###xml 725 729 <span type="species:ncbi:9925">goat</span>
###xml 735 741 <span type="species:ncbi:9986">rabbit</span>
To evaluate the level of immunoglobulin G (IgG) in the serum of vaccinated mice, we incubated A2L2 cells for 1 hour at 37degreesC with either immune serum or control serum diluted 1:100 in PBS, pH 7.2. Fluorescein-isothiocyanate-labeled (FITC-labeled) goat antimouse IgG (Pharmingen, San Diego, CA, USA) diluted 1:1000 in PBS was added to the cells, and incubation continued for 1 hour at 37degreesC. The cells were washed three times in PBS and analyzed by flow cytometry using an EPICS Profile Analyzer (Coulter, Hialeah, FL, USA). As a positive control, A2L2 cells were stained with a 1:1000 dilution of a polyclonal rabbit antibody against p185 (sc-284; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and an FITC-labeled goat anti-rabbit IgG.
###end p 20
###begin title 21
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 21
###begin p 22
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 142 146 <span type="species:ncbi:10090">Mice</span>
Female BALB/c mice 6 to 8 weeks old were obtained from the National Cancer Institute-Frederick Cancer Research Facility (Frederick, MD, USA). Mice were acclimated for at least 1 week before use. Our small-animal facility is approved by the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC).
###end p 22
###begin title 23
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 45 48 45 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 15 19 <span type="species:ncbi:10090">mice</span>
Vaccination of mice with SINCP-neu and Adeno-neu
###end title 23
###begin p 24
###xml 6 10 6 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 290 294 289 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
SINCP-neu was prepared in milligram quantities by Aldevron (Fargo, ND, USA). Intramuscular (i.m.) injections of 0.1 ml containing 100 mug of plasmid DNA formulated with 0.25% bupivacaine (Sigma Chemical, St Louis, MO, USA) were administered to the quadriceps using a 24-gauge needle. Adeno-neu and adenovirus lacking an inserted gene (Adeno-empty) were suspended in 100 mul of 0.85% saline and injected into the quadriceps using a 24-gauge needle. Blood was collected at intervals from the tail vein, and the serum was separated by centrifugation after incubation at 37degreesC for 1 hour and overnight refrigeration.
###end p 24
###begin title 25
Mammary fat pad tumor prevention model
###end title 25
###begin p 26
###xml 492 494 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 611 613 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 651 653 645 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 1133 1135 1127 1129 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 341 345 <span type="species:ncbi:10090">Mice</span>
###xml 831 835 <span type="species:ncbi:10090">mice</span>
###xml 938 942 <span type="species:ncbi:10090">Mice</span>
###xml 1111 1115 <span type="species:ncbi:10090">mice</span>
We used a mammary fat pad tumor prevention model to assess the effect of vaccination on solid tumor development. A2L2 cells from cultures that had reached 75% confluence were harvested by treatment with 0.25% trypsin and 0.02% EDTA for 1 to 3 min at 37degreesC. The cells were washed once in serum-containing culture medium and once in PBS. Mice were anesthetized by inhalation of isoflurane using an apparatus developed by veterinarians at the University of Texas MD Anderson Cancer Center [39]. The fur was shaved over the lateral thorax, and a 5-mm-long incision was made to reveal mammary fat pad number 2 [40]. A 0.1-ml sample containing 2.5 x 104 A2L2 cells in normal saline was injected into the fat pad. The incision was closed with a wound clip. After 7 days, wound clips that had not already fallen off were removed. The mice were then observed daily, and their tumors were measured in perpendicular directions using a caliper. Mice with tumors at least 10 mm in the greater dimension were killed according to our approved Institutional Animal Care and Use protocol. At the end of the experiment, all mice were killed by CO2 inhalation, and all tumors were excised and weighed. Examination of the surface of the lungs during necropsy did not reveal tumor nodules.
###end p 26
###begin title 27
Experimental metastasis prevention model
###end title 27
###begin p 28
###xml 414 416 414 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 546 548 546 548 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 150 154 <span type="species:ncbi:10090">mice</span>
###xml 494 499 <span type="species:ncbi:10090">mouse</span>
###xml 524 528 <span type="species:ncbi:10090">mice</span>
Although a solid tumor develops after injection of A2L2 cells into the mammary fat pad, it is not highly metastatic. The tumor induces moribundity in mice before an appreciable number of lung metastases develop. For this reason, we used an experimental lung metastasis model rather than a spontaneous lung metastasis model to assess the effect of vaccination on lung metastasis. A 0.1-ml sample containing 2.5 x 104 A2L2 cells in normal saline was injected into the tail vein of each immunized mouse. Thirty days later, the mice were killed by CO2 inhalation, and surface lung metastases in each animal were counted.
###end p 28
###begin title 29
ELISPOT analysis of IFNgamma production by immune spleen cells
###end title 29
###begin p 30
###xml 382 384 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 745 747 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 110 114 <span type="species:ncbi:10090">mice</span>
###xml 309 313 <span type="species:ncbi:10090">mice</span>
###xml 491 495 <span type="species:ncbi:10090">mice</span>
To determine the number of interferon-gamma-producing (IFNgamma-producing) cells in the spleens of vaccinated mice, we used an IFNgamma enzyme-linked immunospot (ELISPOT) technique (kit no. 552569; Pharmingen) and used reagents from Pharmingen whenever possible. Immune spleens were dissected from vaccinated mice and prepared exactly as previously described for tetramer analysis [41]. Wells containing only immune spleen cells served as negative controls, and spleen cells from vaccinated mice cultured with 5 mug/ml concanavalin A (Con A) (Sigma-Aldrich, St Louis, MO, USA) overnight served as a positive control. The finished plates were air-dried overnight at room temperature in the dark and sent to ZellNet Consulting (New York, NY, USA [42]), where the spots were counted automatically using an ImmunoSpot Series I analyzer (BD Bioscience, San Diego, CA, USA). If confluence (overlapping spots) was present in wells, the number of spots in a non-confluent area of that well was determined, and the following equation was used to estimate the total number of spots in each well with confluence: total spot number = spot count+2(spot count x % confluence/ [100% - %confluence]).
###end p 30
###begin title 31
Statistical analysis
###end title 31
###begin p 32
###xml 10 12 10 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
Student's t test was performed using Prism 4.0 GraphPad software (San Diego, CA, USA).
###end p 32
###begin title 33
Results
###end title 33
###begin title 34
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 73 76 73 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
Inhibition of solid tumor growth by vaccination with SINCP-neu and Adeno-neu
###end title 34
###begin p 35
###xml 162 166 161 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 494 497 487 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 669 671 659 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 744 748 734 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 861 863 848 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 879 881 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
###xml 319 323 <span type="species:ncbi:10090">mice</span>
###xml 406 410 <span type="species:ncbi:10090">mice</span>
###xml 508 512 <span type="species:ncbi:10090">mice</span>
###xml 726 730 <span type="species:ncbi:10090">mice</span>
To determine the effectiveness of vaccination on solid tumor growth, two groups of 13 mice each were vaccinated once i.m. in the quadriceps with 100 mug of SINCP-neu or SINCP-betagal. Two weeks later, the mice were challenged with A2L2 cells injected into the mammary fat pad. Thirty-five days after the challenge, the mice were killed and if a solid tumor was present, its mass was determined. All of the mice vaccinated with SINCP-betagal developed tumors. In the group vaccinated with SINCP-neu, only six mice developed tumors, and the mean mass of these six tumors was significantly less than the mean mass of the tumors in the SINCP-betagal group (0.63 vs 1.02 g; P = 0.0186). When we calculated the mean mass for all 13 mice in the SINCP-neu group and compared it with the value of the SINCP-betagal group, the difference was significant (0.25 vs 1.02 g; P = 0.0001) (Fig. 1a).
###end p 35
###begin p 36
###xml 82 85 82 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">10 </sup>
###xml 104 108 104 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 440 444 440 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 506 508 506 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 524 526 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 145 149 <span type="species:ncbi:10090">mice</span>
###xml 259 263 <span type="species:ncbi:10090">mice</span>
###xml 346 350 <span type="species:ncbi:10090">mice</span>
###xml 457 461 <span type="species:ncbi:10090">mice</span>
Two groups of 10 mice were each vaccinated i.m. in the quadriceps once with 1 x 1010 particles of Adeno-neu or Adeno-empty. Six weeks later, the mice were challenged with A2L2 cells injected into the mammary fat pad. Thirty-five days after the challenge, the mice were killed and if a solid tumor was present, its mass was determined. All of the mice vaccinated with Adeno-empty developed tumors, whereas in the group vaccinated with Adeno-neu only 1 of 10 mice developed a tumor (mean mass 1.75 vs 0.2 g; P = 0.0001) (Fig. 1b).
###end p 36
###begin p 37
###xml 239 243 236 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
Our findings show that reduced solid tumor growth is attributable to the induction of cellular immunity. This immunity is antigen specific, because it was absent in mice vaccinated with SINCP-betagal or Adeno-empty, both of which lack the neu gene.
###end p 37
###begin title 38
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 78 81 78 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
Inhibition of experimental metastasis by vaccination with SINCP-neu and Adeno-neu
###end title 38
###begin p 39
###xml 160 164 159 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 592 596 585 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 682 684 675 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 700 702 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
###xml 257 261 <span type="species:ncbi:10090">mice</span>
###xml 364 368 <span type="species:ncbi:10090">mice</span>
###xml 500 504 <span type="species:ncbi:10090">mice</span>
###xml 613 617 <span type="species:ncbi:10090">mice</span>
To determine the effectiveness of vaccination on experimental metastasis of A2L2 cells, two groups of five mice each were vaccinated i.m. with 100 mug of SINCP-neu or SINCP-betagal three times at 2-week intervals. Two weeks after the third vaccination, the mice were challenged with A2L2 cells injected into the tail vein. Twenty-one days after the challenge, the mice were killed, the lungs removed, and the number of tumor nodules on the surface of the lungs counted with the naked eye. All of the mice in the SINCP-betagal group had more than 25 surface lung nodules, whereas in the SINCP-neu group all of the mice had between 1 and 10 nodules (mean number of nodules 105 vs 15; P = 0.0079) (Fig. 2a).
###end p 39
###begin p 40
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 382 386 382 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 460 462 460 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 478 480 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 19 23 <span type="species:ncbi:10090">mice</span>
###xml 196 200 <span type="species:ncbi:10090">mice</span>
###xml 312 317 <span type="species:ncbi:10090">mouse</span>
###xml 405 409 <span type="species:ncbi:10090">mice</span>
Two groups of nine mice each were vaccinated once with Adeno-neu or Adeno-empty and 6 weeks later challenged with A2L2 cells injected into the tail vein. Thirty-five days after the challenge, the mice were killed, the lungs removed, and the number of surface lung nodules counted with the naked eye. All but one mouse in the Adeno-empty group had lung nodules, whereas in the Adeno-neu group five of nine mice had lung nodules (mean number of nodules 15 vs 1; P = 0.0078) (Fig. 2b).
###end p 40
###begin p 41
###xml 248 252 245 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 174 178 <span type="species:ncbi:10090">mice</span>
Our results show that inhibition of experimental metastasis is attributable to the induction of cellular immunity. This immunity is antigen specific because it was absent in mice vaccinated with SINCP-betagal or Adeno-empty, both of which lack the neu gene.
###end p 41
###begin title 42
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 73 76 73 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 33 37 <span type="species:ncbi:10090">mice</span>
neu-Specific IgG in the serum of mice vaccinated with SINCP-neu or Adeno-neu
###end title 42
###begin p 43
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 462 466 462 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 564 566 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 617 621 614 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 723 725 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 170 174 <span type="species:ncbi:10090">mice</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
###xml 523 527 <span type="species:ncbi:10090">mice</span>
###xml 590 594 <span type="species:ncbi:10090">mice</span>
###xml 684 688 <span type="species:ncbi:10090">mice</span>
To determine if vaccination induced a humoral immune response to p185, immediately before tumor challenge 0.1 ml of blood was collected from the tail vein of each of the mice treated as described for the experimental metastasis model. The sera for each group were pooled and analyzed for the presence of p185-specific IgG by flow cytometry using the A2L2 cell line as described previously [29] and in Materials and methods. Serum from mice vaccinated with SINCP-neu had a stronger IgG response to A2L2 cells than that from mice vaccinated with SINCP-betagal (Fig. 3a). Likewise, serum from mice vaccinated with Adeno-neu exhibited a stronger IgG response to A2L2 cells than that from mice vaccinated with Adeno-empty (Fig. 3b). These results show that the gene vaccines induce humoral immunity as well as the cellular immunity described above.
###end p 43
###begin title 44
Therapeutic vaccination with SINCP and Adeno
###end title 44
###begin p 45
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 451 455 <span type="species:ncbi:10090">mice</span>
Because SINCP-neu and Adeno-neu were effective as preventive vaccines delivered before tumor cell challenge, we evaluated both vaccines as therapeutic vaccines delivered after tumor cell challenge. Vaccination conditions were the same as those described for the experimental metastasis model. In both the therapeutic mammary fat pad tumor model and the therapeutic experimental metastasis model, neither vaccine prolonged the overall survival rate of mice when delivered after tumor cell challenge (data not shown). Even when administered as early as 2 days after tumor challenge, neither vaccine was effective.
###end p 45
###begin title 46
Therapeutic vaccination with SINCP and Adeno using a prime-boost protocol
###end title 46
###begin p 47
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 536 540 536 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 585 589 582 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
To determine whether the therapeutic effectiveness of the vaccines could be increased by sequential administration, we evaluated a prime-boost protocol in which the mice were primed with a single injection of SINCP 2 days after tumor cell challenge with A2L2 cells and boosted with injections of Adeno 9 and 16 days after the challenge. SINCP was always the prime and Adeno was always the boost, because numerous studies have reported that the most effective protocol is a plasmid followed by a virus [43-47]. All combinations of SINCP-neu or SINCP-betagal used as the prime and Adeno-neu and Adeno-empty used as the boost were tested in both the therapeutic mammary fat pad tumor model and the therapeutic experimental metastasis model.
###end p 47
###begin p 48
###xml 301 305 301 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 329 333 329 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 348 350 348 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 504 508 501 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 603 607 600 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 649 651 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 679 683 676 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 743 747 740 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 387 391 <span type="species:ncbi:10090">mice</span>
In the therapeutic mammary fat pad tumor model, none of the combinations significantly increased the overall survival rate (data not shown). In the therapeutic experimental metastasis model, only one prime-boost combination was effective: the overall survival rate was significantly higher when SINCP-neu was the prime and Adeno-neu was the boost (P = 0.0004) (Fig. 4a). A comparison of mice vaccinated with SINCP-betagal as the prime showed that the overall survival rate was slightly higher when Adeno-neu was the boost than when Adeno-empty was the boost, but that this increase was not as high when neu was in both the prime and the boost (Fig. 4b). Thus, priming with SINCP-neu is essential for the effect, depends on the presence of the neu gene, and cannot be replaced by non-specific stimulation with SINCP-betagal.
###end p 48
###begin title 49
###xml 56 60 <span type="species:ncbi:10090">mice</span>
neu-Specific IgG in the serum of prime-boost-vaccinated mice
###end title 49
###begin p 50
###xml 64 73 64 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 129 133 129 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 177 180 177 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 287 289 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 312 316 309 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 411 413 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 499 501 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 599 601 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 569 573 <span type="species:ncbi:10090">mice</span>
We evaluated the effectiveness of prime-boost vaccination in an in vitro assay. Naive mice were primed by vaccination with SINCP-neu and boosted by vaccination twice with Adeno-neu, or they were primed by vaccination with SINCP-betagal and boosted by vaccination twice with Adeno-empty [48]. The presence of the neu gene in both the prime and the boost resulted in a strong IgG response to the A2L2 cells (Fig. 5a). The IgG response from vaccination with SINCP-betagal followed by Adeno-empty (Fig. 5a) was nearly identical to the IgG level in serum collected from the mice before vaccination (Fig. 5b). These observations indicated that prime-boost vaccination produces strong humoral immunity.
###end p 50
###begin title 51
###xml 79 83 <span type="species:ncbi:10090">mice</span>
Induction of IFNgamma-producing cells in the spleens of prime-boost-vaccinated mice
###end title 51
###begin p 52
###xml 54 57 54 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 170 174 166 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 197 201 193 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 486 490 475 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 508 512 497 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 827 828 805 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 1025 1029 1002 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 1083 1087 1060 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 143 147 <span type="species:ncbi:10090">mice</span>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
###xml 342 346 <span type="species:ncbi:10090">mice</span>
To determine whether prime-boost vaccination produced neu-specific T lymphocytes, we used an IFNgamma ELISPOT assay to compare spleen cells of mice vaccinated with SINCP-neu as the prime and Adeno-neu as the boost with spleen cells of mice vaccinated with SINCP-betagal as the prime and Adeno-empty as the boost. Spleen cells from vaccinated mice were co-cultured overnight with A2L2 cells, and the next day the number of cells producing IFNgamma was determined. Vaccination with SINCP-neu followed by Adeno-neu resulted in a mean of more than 150 IFNgamma-producing cells per million spleen cells at all ratios of effector (spleen cell) to stimulator (A2L2 cells) cells, whereas vaccination with SINCP-betagal followed by Adeno-empty resulted in a mean of fewer than 20 IFNgamma-producing cells per million spleen cells (Fig. 6). As a positive control and possibly as a measure, of a maximum response, spleen cells were stimulated with 5 mug/ml Con A, which resulted in a mean that was comparable to the means obtained with neu in both the prime and the boost. That the presence of neu in both the prime and the boost resulted in IFNgamma production after co-culture with A2L2 cells and that this effect was not seen with vaccination with SINCP-betagal followed by Adeno-empty clearly demonstrated that prime-boost vaccination resulted in antigen-specific induction of cellular immunity.
###end p 52
###begin title 53
Discussion
###end title 53
###begin p 54
###xml 104 108 104 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 233 237 233 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 246 250 246 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 340 344 340 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 373 377 373 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 118 122 <span type="species:ncbi:10090">mice</span>
In this report, we showed that vaccination with a plasmid or adenovirus vaccine containing the gene for neu protected mice from challenge with breast cancer cells. In the mammary fat pad model, a single vaccination with either SINCP-neu or Adeno-neu was effective. In the experimental lung metastasis model, a single vaccination with Adeno-neu was effective, and the SINCP-neu vaccine was effective when delivered three times at 2-week intervals.
###end p 54
###begin p 55
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 65 69 65 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 368 372 365 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 393 395 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 477 481 474 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 556 559 553 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 736 740 733 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 25 29 <span type="species:ncbi:10090">mice</span>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
###xml 283 287 <span type="species:ncbi:10090">mice</span>
In our study, serum from mice vaccinated with SINCP-neu or Adeno-neu contained high levels of IgG that reacted with A2L2 cells, whereas serum from mice vaccinated with SINCP-betagal or Adeno-empty was at background levels. We previously showed that immune serum from gene-vaccinated mice does not react with the parental cell line (66.3) that was transfected with the neu gene to create A2L2 [29]. The level of immunoflourescence resulting from a single vaccination with Adeno-neu was one log greater than that resulting from three vaccinations with SINCP-neu. Taken together with the results described in the previous paragraph for the experimental metastasis model, this finding indicates that at these doses and this schedule, Adeno-neu is the more immunogenic vaccine. Of course, there is no way to accurately compare a plasmid vaccine with a viral vaccine except in relative terms.
###end p 55
###begin p 56
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 330 333 330 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 341 345 341 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 676 678 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
Although both SINCP-neu and Adeno-neu produced robust protection in two tumor-prevention models, both gene vaccines were ineffective when used after A2L2 cells were injected into the mammary fat pad or i.v., even when vaccination was begun only 2 days after tumor cell injection and vaccination was repeated three times for SINCP-neu. Adeno-neu was injected only once in these therapeutic models. Because many publications have described the effectiveness of prime-boost vaccination in which the prime is a plasmid gene vaccine and the boost is a viral gene vaccine, and have shown that priming with a plasmid and boosting with a virus is more effective than the opposite [43,44,47], we tested this strategy in our two therapeutic tumor models.
###end p 56
###begin p 57
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 399 403 396 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 413 417 410 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 787 796 784 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 126 130 <span type="species:ncbi:10090">mice</span>
###xml 461 465 <span type="species:ncbi:10090">mice</span>
In our experimental metastasis model, priming with SINCP-neu followed by boosting twice with Adeno-neu prolonged the lives of mice compared with prime-boost vaccination with SINCP-betagal and Adeno-empty. This effect was seen only in the experimental metastasis model and not in the experimental mammary fat pad model, and no other prime-boost combination worked. Although this combination of SINCP-neu and Adeno-neu was able to increase the survival rate, all mice eventually succumbed to tumor growth and were killed because of moribundity. We also found that prime-boost vaccination results in antigen-specific induction of both cellular and humoral immunity. A question that cannot be answered by our findings is the relative role of cellular immunity versus humoral immunity in the in vitro antitumor effect.
###end p 57
###begin p 58
###xml 204 208 204 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 252 255 252 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 323 326 323 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 362 365 362 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 861 870 861 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 902 906 902 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 915 919 915 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 1123 1126 1123 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 166 174 <span type="species:ncbi:9606">patients</span>
###xml 231 239 <span type="species:ncbi:9606">patients</span>
###xml 922 930 <span type="species:ncbi:9606">patients</span>
With the mandate to move promising laboratory findings to the clinic, it is most important to evaluate the implications of these findings with regard to treatment of patients. A gene vaccine against HER2/neu could be effective for patients with a HER2/neu-expressing tumor but could not be rationally used to manage a HER2/neu-negative tumor. Many types of HER2/neu-expressing tumors are noteworthy for their aggressive growth and high metastatic potential [50]. Our data indicate that combined vaccination in a prime-boost schedule may be the most likely to produce a clinical effect. However, these vaccines require phase I toxicity testing individually before they could be evaluated in a prime-boost protocol. A phase I/II study may yield valuable information regarding increased survival rates and induction of cellular and humoral immunity as measured by in vitro assays. Testing of either SINCP-neu or Adeno-neu in patients will require the production of clinical-grade material, which could be less of a hurdle for a plasmid than for a virus. Nonetheless, our data identify two promising gene vaccines against HER2/neu, an antigen associated with aggressive tumor growth and metastasis.
###end p 58
###begin title 59
Conclusion
###end title 59
###begin p 60
###xml 136 139 136 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 168 171 168 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 629 638 629 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 24 28 <span type="species:ncbi:10090">mice</span>
We demonstrated that in mice, vaccination with a plasmid gene vaccine and an adenovirus gene vaccine, each containing the gene for HER2/neu, prevented growth of a HER2/neu-expressing breast cancer cell line injected into the mammary fat pad or i.v. The gene vaccines were not effective individually in therapeutic vaccine models in which vaccination took place after tumor cells were injected. However, sequential administration of the vaccines in a prime-boost protocol was therapeutically effective when the tumor cells were injected i.v. The vaccines induced high levels of both cellular and humoral immunity as determined by in vitro assessment. Clinical evaluation of these vaccines, particularly when used sequentially, is justified.
###end p 60
###begin title 61
Abbreviations
###end title 61
###begin p 62
Adeno = adenovirus; Con A = concanavalin A; EDTA = ethylenediaminetetraacetic acid; ELISPOT = enzyme-linked immunospot; FITC = fluorescein isothiocyanate; i.m. = intramuscular or intramuscularly; i.v. = intravenous or intravenously; IgG = immunoglobulin G; IFNgamma = interferon gamma ; PBS = phosphate-buffered saline.
###end p 62
###begin title 63
Competing interests
###end title 63
###begin p 64
The authors declare that they have no competing interests.
###end p 64
###begin title 65
Authors' contributions
###end title 65
###begin p 66
###xml 270 273 270 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
The authors' contributions to this research are reflected in the order shown. XW performed all molecular biology in Dr. Lachman's laboratory, all animal experiments and all laboratory analysis; J-PW was responsible for cell culture; X-MR prepared and purified the Adeno-neu; JEP supervised the initial animal experimentation and developed the tumor model; HSZ performed all molecular biology associated with the adenovirus work and LBL supervised all aspects of the research and wrote the original manuscript. All authors read and approved the final manuscript.
###end p 66
###begin title 67
Acknowledgements
###end title 67
###begin p 68
This research was supported by the US Army Medical Research and Materiel Command, Department of Defense Breast Cancer Research Program grant BC980071, the WM Keck Center for Cancer Gene Therapy, and National Cancer Institute grant CA16672. We thank Galina M Kiriakova in the Department of Cancer Biology for her cooperation and outstanding technical assistance. We also thank Elizabeth L Hess of the Department of Scientific Publications for expert editing of the manuscript.
###end p 68
###begin article-title 69
Update on the management of advanced breast cancer
###end article-title 69
###begin article-title 70
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 43 48 <span type="species:ncbi:9606">human</span>
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
###end article-title 70
###begin article-title 71
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
###end article-title 71
###begin article-title 72
###xml 85 100 <span type="species:ncbi:10090">transgenic mice</span>
Towards a long-lasting immune prevention of HER2 mammary carcinomas: directions from transgenic mice
###end article-title 72
###begin article-title 73
DNA vaccines to attack cancer
###end article-title 73
###begin article-title 74
###xml 6 11 <span type="species:ncbi:9606">human</span>
###xml 58 93 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response
###end article-title 74
###begin article-title 75
###xml 57 63 <span type="species:ncbi:9606">humans</span>
Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine
###end article-title 75
###begin article-title 76
###xml 97 103 <span type="species:ncbi:9606">humans</span>
###xml 145 162 <span type="species:ncbi:10407">hepatitis B virus</span>
Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine
###end article-title 76
###begin article-title 77
###xml 82 90 82 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env/rev </italic>
###xml 46 81 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines
###end article-title 77
###begin article-title 78
Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers
###end article-title 78
###begin article-title 79
Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device
###end article-title 79
###begin article-title 80
###xml 43 48 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Enhancement of cellular immune response in HIV-1 seropositive individuals: a DNA-based trial
###end article-title 80
###begin article-title 81
###xml 21 26 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 77 83 <span type="species:ncbi:9606">humans</span>
DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans
###end article-title 81
###begin article-title 82
###xml 22 30 <span type="species:ncbi:9606">patients</span>
Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen
###end article-title 82
###begin article-title 83
###xml 133 141 <span type="species:ncbi:9606">patients</span>
Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients
###end article-title 83
###begin article-title 84
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma
###end article-title 84
###begin article-title 85
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma
###end article-title 85
###begin article-title 86
Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial
###end article-title 86
###begin article-title 87
Cancer immunotherapy: moving beyond current vaccines
###end article-title 87
###begin article-title 88
###xml 90 98 <span type="species:ncbi:9606">patients</span>
A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer
###end article-title 88
###begin article-title 89
Part I: Vaccines for solid tumours
###end article-title 89
###begin article-title 90
Part II: Vaccines for haematological malignant disorders
###end article-title 90
###begin article-title 91
Correspondence 1: Cancer vaccines: pessimism in check
###end article-title 91
###begin article-title 92
Control of viral rebound through therapeutic immunization with DermaVir
###end article-title 92
###begin article-title 93
Gene therapy meets vaccine development
###end article-title 93
###begin article-title 94
Alphavirus vectors for vaccine production and gene therapy
###end article-title 94
###begin article-title 95
Alphavirus vectors for cancer gene therapy
###end article-title 95
###begin article-title 96
Alphaviruses and their derived vectors as anti-tumor agents
###end article-title 96
###begin article-title 97
###xml 78 82 <span type="species:ncbi:10090">mice</span>
DNA vaccination against neu reduces breast cancer incidence and metastasis in mice
###end article-title 97
###begin article-title 98
Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways
###end article-title 98
###begin article-title 99
An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells
###end article-title 99
###begin article-title 100
Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens
###end article-title 100
###begin article-title 101
Adenoviruses as vaccine vectors
###end article-title 101
###begin article-title 102
Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12
###end article-title 102
###begin article-title 103
###xml 27 31 <span type="species:ncbi:10090">mice</span>
Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector
###end article-title 103
###begin article-title 104
###xml 24 29 <span type="species:ncbi:9606">human</span>
Virus-based vectors for human vaccine applications
###end article-title 104
###begin article-title 105
Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted
###end article-title 105
###begin article-title 106
Production of helper-dependent adenovirus vector relies on helper virus structure and complementing
###end article-title 106
###begin article-title 107
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis
###end article-title 107
###begin article-title 108
###xml 33 39 <span type="species:ncbi:9606">people</span>
Prime boost vaccines power up in people
###end article-title 108
###begin article-title 109
The prime-boost strategy: exciting prospects for improved vaccination
###end article-title 109
###begin article-title 110
Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers
###end article-title 110
###begin article-title 111
DNA vaccines: designing strategies against parasitic infections
###end article-title 111
###begin article-title 112
###xml 92 95 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 134 138 <span type="species:ncbi:10090">mice</span>
Combination of DNA vaccine and adenovirus vector by cutaneous administration induced strong HIV-specific cellular immune responses in mice
###end article-title 112
###begin article-title 113
Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC tetramer, ELISpot, and intracellular cytokine analysis
###end article-title 113
###begin article-title 114
Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity
###end article-title 114
###begin article-title 115
HER1/EGFR targeting: refining the strategy
###end article-title 115
###begin title 116
Figures and Tables
###end title 116
###begin p 117
###xml 141 145 141 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 213 216 213 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 236 240 233 237 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 254 258 251 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 326 329 323 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 384 387 381 384 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 104 108 <span type="species:ncbi:10090">mice</span>
###xml 167 180 <span type="species:ncbi:11034">Sindbis virus</span>
###xml 204 207 <span type="species:ncbi:10116">rat</span>
###xml 317 320 <span type="species:ncbi:10116">rat</span>
###xml 474 478 <span type="species:ncbi:10090">mice</span>
###xml 592 596 <span type="species:ncbi:10090">mice</span>
###xml 708 713 <span type="species:ncbi:10090">mouse</span>
Protection from tumor challenge in the mammary fat pad after vaccination with SINCP or Adeno. Groups of mice were vaccinated once with SINCP-neu (a plasmid containing Sindbis virus genes and the gene for rat HER2/neu) or SINCP-betagal. (a) or with Adeno-neu (an E1,E2a-deleted adenovirus also containing the gene for rat HER2/neu) or Adeno-empty (adenovirus lacking an inserted gene) (b). Two weeks after vaccination with SINCP and 6 weeks after vaccination with Adeno, the mice were challenged with A2L2 cells injected into a mammary fat pad. Thirty-five days after the tumor challenge, the mice were killed and if a solid tumor was present, the mass of the tumor was determined. Each symbol represents one mouse. Horizontal bars indicate means.
###end p 117
###begin p 118
###xml 157 161 157 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 229 232 229 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 252 256 249 253 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 275 279 272 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 347 350 344 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 405 408 402 405 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 93 97 <span type="species:ncbi:10090">mice</span>
###xml 183 196 <span type="species:ncbi:11034">Sindbis virus</span>
###xml 220 223 <span type="species:ncbi:10116">rat</span>
###xml 338 341 <span type="species:ncbi:10116">rat</span>
###xml 504 508 <span type="species:ncbi:10090">mice</span>
###xml 698 702 <span type="species:ncbi:10090">mice</span>
###xml 816 821 <span type="species:ncbi:10090">mouse</span>
Protection from intravenous tumor challenge after vaccination with SINCP or Adeno. Groups of mice were vaccinated three times at 2-week intervals with SINCP-neu (a plasmid containing Sindbis virus genes and the gene for rat HER2/neu) or SINCP-betagal. (a) or once with Adeno-neu (an E1,E2a-deleted adenovirus also containing the gene for rat HER2/neu) or Adeno-empty (adenovirus lacking an inserted gene) (b). Two weeks after the final vaccination with SINCP or 6 weeks after vaccination with Adeno, the mice were challenged with A2L2 cells injected into the tail vein. Twenty-one days after the challenge in SINCP-vaccinated animals or 35 days after the challenge in Adeno-vaccinated animals, the mice were killed and the number of tumor nodules on the surfaces of the lungs was counted. Each symbol represents one mouse. Horizontal bars indicate means.
###end p 118
###begin p 119
###xml 170 174 170 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 242 245 242 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 265 269 262 266 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 318 322 315 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 390 393 387 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 448 451 445 448 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
###xml 154 158 <span type="species:ncbi:10090">mice</span>
###xml 196 209 <span type="species:ncbi:11034">Sindbis virus</span>
###xml 233 236 <span type="species:ncbi:10116">rat</span>
###xml 381 384 <span type="species:ncbi:10116">rat</span>
###xml 539 543 <span type="species:ncbi:9925">goat</span>
Flow cytometric analysis, using A2L2 cells, of serum from mice vaccinated with SINCP or Adeno. Serum was collected 2 weeks after the third vaccination of mice with SINCP-neu (a plasmid containing Sindbis virus genes and the gene for rat HER2/neu) or SINCP-betagal. (a) or 6 weeks after a single vaccination with Adeno-neu (an E1,E2a-deleted adenovirus also containing the gene for rat HER2/neu) or Adeno-empty (adenovirus lacking an inserted gene) (b). The immune serum was diluted with PBS (1:100), and fluorescein-isothiocyanate-labeled goat antimouse IgG diluted in PBS (1:1000) was used as the secondary antibody.
###end p 119
###begin p 120
###xml 222 226 222 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 294 297 294 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 380 384 377 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 452 455 449 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 511 515 508 512 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 562 566 559 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 576 580 573 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 646 650 640 644 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 697 701 691 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 711 715 705 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 774 777 765 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 779 781 770 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 99 103 <span type="species:ncbi:10090">Mice</span>
###xml 183 187 <span type="species:ncbi:10090">mice</span>
###xml 248 261 <span type="species:ncbi:11034">Sindbis virus</span>
###xml 285 288 <span type="species:ncbi:10116">rat</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 443 446 <span type="species:ncbi:10116">rat</span>
###xml 535 539 <span type="species:ncbi:10090">mice</span>
###xml 594 598 <span type="species:ncbi:10090">mice</span>
###xml 670 674 <span type="species:ncbi:10090">mice</span>
###xml 729 733 <span type="species:ncbi:10090">mice</span>
Survival in a therapeutic metastasis model after vaccination with SINCP (prime) and Adeno (boost). Mice were given injections into the tail vein of A2L2 cells on day 0. On day 2, the mice were vaccinated with either SINCP-neu (a plasmid containing Sindbis virus genes and the gene for rat HER2/neu) or SINCP-betagal and on days 9 and 16 the mice were vaccinated with either Adeno-neu (an E1,E2a-deleted adenovirus also containing the gene for rat HER2/neu) or Adeno-empty (adenovirus lacking an inserted gene). (a) Overall survival of mice vaccinated with SINCP-neu and Adeno-neu compared with mice vaccinated with SINCP-betagal and Adeno-empty. (b) Overall survival of mice vaccinated with SINCP-neu and Adeno-neu compared with mice vaccinated with SINCP-betagal and Adeno-neu. P values were determined by a log-rank test of Kaplan-Meier survival curves.
###end p 120
###begin p 121
###xml 132 136 132 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 204 207 204 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 265 269 265 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 337 340 337 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 518 522 515 519 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 638 642 635 639 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 56 60 <span type="species:ncbi:10090">mice</span>
###xml 100 104 <span type="species:ncbi:10090">mice</span>
###xml 158 171 <span type="species:ncbi:11034">Sindbis virus</span>
###xml 195 198 <span type="species:ncbi:10116">rat</span>
###xml 328 331 <span type="species:ncbi:10116">rat</span>
###xml 701 705 <span type="species:ncbi:9925">goat</span>
Flow cytometric analysis using A2L2 cells of serum from mice vaccinated with SINCP and Adeno. Naive mice were vaccinated with SINCP-neu (a plasmid containing Sindbis virus genes and the gene for rat HER2/neu) as the prime and twice, at 2-week intervals, with Adeno-neu (an E1,E2a-deleted adenovirus also containing the gene for rat HER2/neu) as the boost; or they were vaccinated with SINCP-betagal as the prime and then twice, at 2-week intervals, with Adeno-empty (adenovirus lacking an inserted gene) as the boost. (a) Immune serum collected 2 weeks after the second Adeno vaccination was diluted 1:100 and analyzed by flow cytometry. (b) A2L2 cells treated with fluorescein-isothiocyanate-labeled goat antimouse IgG (secondary antibody) and serum collected before vaccination (prebleed) served as the negative controls, and A2L2 cells treated with a commercial polyclonal antibody against p185 served as the positive control.
###end p 121
###begin p 122
###xml 139 143 135 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 211 214 207 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 264 268 260 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 336 339 332 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
###xml 165 178 <span type="species:ncbi:11034">Sindbis virus</span>
###xml 202 205 <span type="species:ncbi:10116">rat</span>
###xml 327 330 <span type="species:ncbi:10116">rat</span>
IFNgamma ELISPOT analysis of spleen cells from mice vaccinated with SINCP (prime) and Adeno (boost). Naive mice were vaccinated with SINCP-neu (a plasmid containing Sindbis virus genes and the gene for rat HER2/neu) and then twice, at 2-week intervals, with Adeno-neu (an E1,E2a-deleted adenovirus also containing the gene for rat HER2/neu). Spleen cells were collected 2 weeks after the second Adeno vaccination and were cultured overnight with 5 mug/ml concanavalin A, without stimulation, or with A2L2 cells at three different effector:stimulator ratios. The number of IFNgamma-secreting cells was determined using a commercial ELISPOT procedure and antibody pair. Horizontal bars indicate means. IFNgamma, interferon gamma.
###end p 122

